Elutia (NASDAQ:ELUT) Rating Reiterated by Cantor Fitzgerald

Elutia (NASDAQ:ELUTGet Free Report)‘s stock had its “overweight” rating restated by investment analysts at Cantor Fitzgerald in a research report issued on Tuesday, Benzinga reports. They currently have a $8.00 price objective on the stock. Cantor Fitzgerald’s price objective indicates a potential upside of 406.30% from the company’s current price.

Elutia Trading Up 27.4 %

Shares of ELUT traded up $0.34 during trading hours on Tuesday, reaching $1.58. 12,161,354 shares of the company traded hands, compared to its average volume of 192,386. Elutia has a 12 month low of $1.10 and a 12 month high of $9.01. The firm has a market capitalization of $25.68 million, a price-to-earnings ratio of -0.72 and a beta of -0.09.

About Elutia

(Get Free Report)

Elutia Inc, a commercial-stage company, engages in developing and commercializing drug-eluting biomatrix technology to enhance surgical outcomes. It offers CanGaroo Envelope, which is used for the stabilization of implantable cardiac devices, such as pacemakers and defibrillators. The company also engages in the development of CanGaroo RM for delivery directly to the surgical site.

Recommended Stories

Receive News & Ratings for Elutia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elutia and related companies with MarketBeat.com's FREE daily email newsletter.